Release Summary

ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST SUBJECTS IN PHASE 2B GI SAFETY STUDY FOR LEAD DRUG, ATB-346

Antibe Therapeutics Inc.